Raja, M (2017) Preparation and Evaluation of Nanoparticles Containing Imatinib Mesylate and the Complex of Imatinib Mesylate Cobalt (II) Chloride. Masters thesis, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore.
|
Text
260103017raja.pdf Download (5MB) | Preview |
Abstract
INTRODUCTION:Nanotechnology, the term invented by Norio taniguchi in 1974 at the University of Tokyo, provides opportunities to assimilate science and technology in life and physical sciences at nanolevel. Nanotechnology is the integration of science and engineering disciplines to produce products either with or containing nanoscale particles. Thus, it is applied in various areas of biomedical sciences. Indeed, this technology helps to improve the innovation of biomarkers, helps in molecular diagnosis, drug delivery, regenerative medicine, cellular trafficking, bio imaging and gene delivery. OBJECTIVE: 1. To formulate Imatinib Mesylate nanoparticles to treat leukemia, especially Philadelphia positive Chronic Myeloid Leukemia (ph+CML) and Chronic Eosinophillic Leukemia (CEL) using natural and synthetic polymers. 2. To formulate Imatinib Mesylate nanoparticles reduce severe side effects such as muscle cramps, stomach pain, musculoskeletal pain. 3. To reduce the frequency of dosage form, facilitate the drug targeting and to overcome drug resistance. To check the compatibility between the Imatinib Mesylate nanoparticles with natural polymers (Moringa oleifera, Linseed, Badam) and synthetic polymers (Poly vinyl alcohol, Hydroxy Propyl Methyl Cellulose, Eudragit) by FT-IR. 4. To perform the In vitro evaluation of formulated Imatinib Mesylate nanoparticles and optimize the formulations. 5. To complex the Imatinib Mesylate formulation with anti-proliferative agent in the optimized. 6. To perform In vitro evaluation of Imatinib Mesylate nanoparticles complexed with Cobalt (II) Chloride. 7. To perform the acute toxicity study of Imatinib Mesylate nanoparticles complexation. (CoCl2 NPs) by OECD guidelines 420 using female wistar rat model. 8. To perform the cancer activity study of CoCl2 NPs using to treat the male swiss albino mice(Dalton’s Lymphoma Ascities cell line) 9. To test the stability of the formulated Imatinib Mesylate nanoparticles. SUMMARY: Main objective of in this study to formulate Imatinib Mesylate nanoparticles to treat leukemia, especially Philadelphia positive Chronic Myeloid Leukemia (ph+ CML) and Chronic Eosinophillic Leukemia (CEL) using natural and synthetic polymers. Imatinib Mesylate nanoparticles reduce severe side effects such as muscle cramps, stomach pain, musculoskeletal pain and reduce the frequency of dosage form, facilitate the drug targeting and to overcome drug resistance. So the present work was aimed to formulate a novel approach to enhance the delivery of drug by encapsulating it into the nanoparticle system whereby the dose of the drug administered can be lowered to control the night time seizures. The present work aimed to formulate stable Imatinib Mesylate nanoparticles by using various synthetic and natural polymers Poly Vinyl alcohol, Hydroxy Propyl Methyl Cellulose, Eudragit, Moringa oleifera, Badam, Linseed. The polymer were found to be economic, biocompatible and easily available. Imatinib Mesylate nanoparticles were prepared by using solvent evaporation method without the addition of surfactants and charge inducing agents, having vesicle size in the range of 400-800 nm. FTIR and UV spectral studies showed that the spectra obtained with sample drug were matched with standard spectra of pure drug. This shows that the obtained drug sample was Imatinib Mesylate. CONCLUSION: Imatinib Mesylate nanoparticles have been successfully prepared by solvent evaporation method. HPMC, PVA, Eudragit, Moringa oleifera, Linseed, Badam were used as polymers for the preparation of Imatinib Mesylate nanoparticles. Imatinib Mesylate nanoparticles were prepared by solvent evaporation method using various synthetic and natural polymers ratio of 1:1,1:2 respectively. Based on this physiochemical characterization in vitro drug release kinetics of Imatinib Mesylate nanoparticles showed 91.2% of drug at the end of 48th hrs. The F3 formulation complexed with Cobalt (II) Chloride (CoCl2 NPs) (F13 gives in vitro drug release for 95.4% The present study was carried out to evaluate the anti-tumor effect of CoCl2NPs in DLA- bearing mice. The CONPs treated animals at dose of 200 and 400 mg/kg significantly inhibited the tumor volume, and brought back the haematological parameters to more or less to normal levels. In tumor control group, an increase in the volume of ascetic fluid was observed. Ascites fluid is the direct nutritional source for tumor cells and a rapid increase in volume of ascites fluid with tumor growth would be a means to meet the nutritional requirement of tumor cells. Treatment with CoCl2NPs increased the percentage the tryphan blue positive dead cells in tumor bearing mice. The reliable criteria for assessing the value of any anti-cancer drug are the prolongation of the life span of animals. The CoCl2NPs decreased the ascites fluid volume, viable cell count and increased the percentage of life span of animals. Thus, it may be concluded that the reason for decreasing the nutritional fluid volume and arresting the tumor growth, might be due to increase in life span of DLA- bearing mice.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | REG.No.261510155 |
| Uncontrolled Keywords: | Nanoparticles Containing Imatinib Mesylate ; Imatinib Mesylate Cobalt (II) Chloride |
| Subjects: | PHARMACY > Pharmaceutics |
| Depositing User: | Ravindran C |
| Date Deposited: | 23 Mar 2018 08:46 |
| Last Modified: | 23 Mar 2018 08:46 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/6480 |
Actions (login required)
 |
View Item |
